SG11201405164QA - Mice that produce antigen-binding proteins with ph-dependent binding characteristics - Google Patents
Mice that produce antigen-binding proteins with ph-dependent binding characteristicsInfo
- Publication number
- SG11201405164QA SG11201405164QA SG11201405164QA SG11201405164QA SG11201405164QA SG 11201405164Q A SG11201405164Q A SG 11201405164QA SG 11201405164Q A SG11201405164Q A SG 11201405164QA SG 11201405164Q A SG11201405164Q A SG 11201405164QA SG 11201405164Q A SG11201405164Q A SG 11201405164QA
- Authority
- SG
- Singapore
- Prior art keywords
- mice
- produce antigen
- binding
- dependent
- binding proteins
- Prior art date
Links
- 241000699670 Mus sp. Species 0.000 title 1
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261611950P | 2012-03-16 | 2012-03-16 | |
US201261613352P | 2012-03-20 | 2012-03-20 | |
US201261736930P | 2012-12-13 | 2012-12-13 | |
PCT/US2013/031834 WO2013138681A1 (en) | 2012-03-16 | 2013-03-15 | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201405164QA true SG11201405164QA (en) | 2014-10-30 |
Family
ID=48014364
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201607727PA SG10201607727PA (en) | 2012-03-16 | 2013-03-15 | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
SG11201405164QA SG11201405164QA (en) | 2012-03-16 | 2013-03-15 | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201607727PA SG10201607727PA (en) | 2012-03-16 | 2013-03-15 | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
Country Status (14)
Country | Link |
---|---|
US (2) | US9301510B2 (en) |
EP (1) | EP2825035A1 (en) |
JP (1) | JP2015512245A (en) |
KR (1) | KR20140134672A (en) |
CN (2) | CN104302170B (en) |
AU (2) | AU2013204581B2 (en) |
BR (1) | BR112014022853A2 (en) |
CA (1) | CA2865644A1 (en) |
HK (1) | HK1200271A1 (en) |
MX (1) | MX2014011047A (en) |
MY (1) | MY173376A (en) |
RU (1) | RU2014141536A (en) |
SG (2) | SG10201607727PA (en) |
WO (1) | WO2013138681A1 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
DK2517557T4 (en) | 2009-07-08 | 2023-09-25 | Kymab Ltd | Animal models and therapeutic molecules |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
KR20130097156A (en) | 2010-07-26 | 2013-09-02 | 트리아니, 인코포레이티드 | Transgenic animals and methods of use |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
KR20230005405A (en) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb-specific Fc antibody |
EP3839049A3 (en) | 2011-09-19 | 2021-10-20 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
RU2739792C1 (en) | 2011-11-30 | 2020-12-28 | Чугаи Сейяку Кабусики Кайся | Carrier containing a drug into a cell for forming an immune complex |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
CA2865645A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing immunoglobulin sequences ph-sensitive for antigen building |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
EA028244B1 (en) | 2012-08-13 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS |
KR20210084688A (en) | 2012-08-24 | 2021-07-07 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb-specific Fc region variant |
ES2876009T3 (en) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Heterodimerized polypeptide |
HUE039214T2 (en) * | 2013-02-20 | 2018-12-28 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
WO2014163101A1 (en) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc region variant |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
EP3051942B1 (en) | 2013-10-01 | 2020-09-02 | Kymab Limited | Animal models and therapeutic molecules |
WO2015081306A2 (en) * | 2013-11-29 | 2015-06-04 | Escape Therapeutics, Inc. | Peptide tyrosinase activators |
TWI808330B (en) | 2014-12-19 | 2023-07-11 | 日商中外製藥股份有限公司 | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE |
SG10201907215QA (en) | 2015-02-05 | 2019-09-27 | Chugai Pharmaceutical Co Ltd | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof |
JP2018525007A (en) | 2015-08-24 | 2018-09-06 | トリアンニ インコーポレイテッドTrianni,Inc. | Enhanced immunoglobulin production |
WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
JP7141336B2 (en) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | Anti-myostatin antibodies and methods of use |
IL260743B2 (en) | 2016-02-04 | 2024-03-01 | Trianni Inc | Enhanced production of immunoglobulins |
EP3457840B1 (en) | 2016-05-20 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
WO2017210586A1 (en) * | 2016-06-03 | 2017-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
EP3481864A1 (en) | 2016-07-08 | 2019-05-15 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
SG11201801024XA (en) | 2016-08-05 | 2018-05-30 | Chugai Pharmaceutical Co Ltd | Therapeutic or preventive compositions for il-8-related diseases |
CN108299557A (en) * | 2017-01-13 | 2018-07-20 | 杭州翰思生物医药有限公司 | IgG classes antibody is improved to the binding affinity of FcRn and extends the method for its serum half-life |
AU2018255938A1 (en) | 2017-04-21 | 2019-10-31 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
EP3704148A1 (en) | 2017-10-31 | 2020-09-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
CN116514959A (en) | 2018-03-24 | 2023-08-01 | 瑞泽恩制药公司 | Genetically modified non-human animals for producing therapeutic antibodies against peptide-MHC complexes, methods of making and uses thereof |
JP7328243B2 (en) | 2018-03-26 | 2023-08-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Humanized rodents for testing therapeutic agents |
PL3629720T3 (en) | 2018-06-14 | 2022-05-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
CN110669778A (en) * | 2019-09-19 | 2020-01-10 | 上海药明生物技术有限公司 | Rapid modification and screening method for pH-dependent binding activity of antibody |
WO2022056276A1 (en) | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
US20240065239A1 (en) | 2020-12-16 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
EP4051700A1 (en) | 2020-12-23 | 2022-09-07 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991012023A2 (en) | 1990-02-16 | 1991-08-22 | Boston Biomedical Research Institute | Hybrid reagents capable of selectively releasing molecules into cells |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69133476T2 (en) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgenic mice capable of producing heterologous antibodies |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US7067284B1 (en) | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US5999908A (en) | 1992-08-06 | 1999-12-07 | Abelow; Daniel H. | Customer-based product design module |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP3876002B2 (en) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | Novel methods for producing anti-human antigen receptors and their use |
ATE299938T1 (en) | 1997-05-02 | 2005-08-15 | Genentech Inc | A METHOD FOR PRODUCING MULTI-SPECIFIC ANTIBODIES THAT POSSESS HETEROMULTIMER AND COMMON COMPONENTS |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
AU750453B2 (en) | 1997-10-03 | 2002-07-18 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
MXPA03002046A (en) | 2000-09-08 | 2003-07-24 | Massachusetts Inst Technology | G-csf analog compositions and methods. |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
CA2468565C (en) | 2001-11-30 | 2014-06-03 | Abgenix, Inc. | Transgenic animals bearing human iglambda light chain genes |
CA2488836A1 (en) | 2002-06-12 | 2003-12-24 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
PT2314629E (en) | 2002-07-18 | 2014-01-22 | Merus B V | Recombinant production of mixtures of antibodies |
EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
US8337841B2 (en) | 2003-01-21 | 2012-12-25 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for antibody light chains |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
EP2395017A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
CN1560081A (en) | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | Preparing human source monoclone antibody by mouse capable of producing human IgGl weight chain-k light chain and application thereof |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
US7294754B2 (en) | 2004-10-19 | 2007-11-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
US7585504B2 (en) | 2004-10-22 | 2009-09-08 | Medimmune, Llc | High affinity antibodies against HMGB1 and methods of use thereof |
AU2006242854A1 (en) | 2005-04-29 | 2006-11-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Transgenic animals and methods of making recombinant antibodies |
AU2006322445B2 (en) | 2005-12-05 | 2011-05-12 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
JP5514539B2 (en) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
EP2374818B1 (en) | 2006-06-02 | 2012-12-19 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
RU2448979C2 (en) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies to delta-like human ligand-4 |
CN101688228B (en) | 2007-03-13 | 2014-12-24 | 国家犾太健康中心 | Methods for generation of antibodies |
ITMI20071522A1 (en) | 2007-07-27 | 2009-01-28 | Areta Internat S R L | IDIOTYPIC VACCINE |
EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
MX369784B (en) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Method of modifying isoelectric point of antibody via amino acid substitution in cdr. |
CN107551270A (en) | 2008-04-11 | 2018-01-09 | 中外制药株式会社 | The antigen binding molecules combined repeatedly with the antigen of multiple molecules |
CA2729095C (en) | 2008-06-27 | 2018-12-04 | Merus B.V. | Method for producing a transgenic murine mammal |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
DK2346994T3 (en) | 2008-09-30 | 2022-02-28 | Ablexis Llc | Knock-in mice for the production of chimeric antibodies |
JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
MX2011007660A (en) | 2008-12-18 | 2011-08-17 | Kingdon Craig R | Non-human transgenic animals expressing humanised antibodies and use therof. |
US8808136B2 (en) | 2009-05-07 | 2014-08-19 | Volvo Construction Equipment Ab | Working machine and a method for operating a working machine |
KR101747103B1 (en) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2011158009A1 (en) | 2010-06-17 | 2011-12-22 | Kymab Limited | Animal models and therapeutic molecules |
DK2517557T4 (en) | 2009-07-08 | 2023-09-25 | Kymab Ltd | Animal models and therapeutic molecules |
ES2595376T3 (en) | 2009-12-10 | 2016-12-29 | Regeneron Pharmaceuticals, Inc. | Mice that produce heavy chain antibodies |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
HUE029785T2 (en) | 2010-02-08 | 2017-04-28 | Regeneron Pharma | Common light chain mouse |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
KR20150002894A (en) * | 2010-03-11 | 2015-01-07 | 리나트 뉴로사이언스 코프. | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
TWI667346B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
BR112012033248A2 (en) | 2010-06-22 | 2017-11-28 | Regeneron Pharma | mice expressing a light chain with human lip variable and mouse constant regions |
DE14176593T1 (en) | 2011-02-25 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
PL3572517T3 (en) | 2011-08-05 | 2021-10-04 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
MX366269B (en) | 2011-09-30 | 2019-07-04 | Chugai Pharmaceutical Co Ltd | Ion concentration-dependent binding molecule library. |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
NZ630637A (en) | 2012-03-06 | 2016-09-30 | Regeneron Pharma | Common light chain mouse |
US20140013456A1 (en) * | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
CA2865645A1 (en) * | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing immunoglobulin sequences ph-sensitive for antigen building |
MX2014014891A (en) | 2012-06-05 | 2015-06-17 | Regeneron Pharma | Methods for making fully human bispecific antibodies using a common light chain. |
HUE039214T2 (en) | 2013-02-20 | 2018-12-28 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
-
2013
- 2013-03-15 MY MYPI2014002412A patent/MY173376A/en unknown
- 2013-03-15 RU RU2014141536A patent/RU2014141536A/en not_active Application Discontinuation
- 2013-03-15 CA CA2865644A patent/CA2865644A1/en not_active Abandoned
- 2013-03-15 MX MX2014011047A patent/MX2014011047A/en unknown
- 2013-03-15 CN CN201380025685.9A patent/CN104302170B/en not_active Expired - Fee Related
- 2013-03-15 CN CN201610701461.0A patent/CN106318951A/en active Pending
- 2013-03-15 KR KR1020147025490A patent/KR20140134672A/en active IP Right Grant
- 2013-03-15 WO PCT/US2013/031834 patent/WO2013138681A1/en active Application Filing
- 2013-03-15 EP EP13713036.5A patent/EP2825035A1/en not_active Withdrawn
- 2013-03-15 JP JP2015500640A patent/JP2015512245A/en active Pending
- 2013-03-15 SG SG10201607727PA patent/SG10201607727PA/en unknown
- 2013-03-15 SG SG11201405164QA patent/SG11201405164QA/en unknown
- 2013-03-15 AU AU2013204581A patent/AU2013204581B2/en active Active
- 2013-03-15 BR BR112014022853A patent/BR112014022853A2/en not_active Application Discontinuation
- 2013-03-15 US US13/832,309 patent/US9301510B2/en not_active Expired - Fee Related
-
2015
- 2015-01-29 HK HK15101010.7A patent/HK1200271A1/en unknown
-
2016
- 2016-02-17 US US15/046,105 patent/US20160229906A1/en not_active Abandoned
- 2016-06-16 AU AU2016204066A patent/AU2016204066A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130247235A1 (en) | 2013-09-19 |
AU2013204581A1 (en) | 2013-10-03 |
JP2015512245A (en) | 2015-04-27 |
CN104302170B (en) | 2016-09-28 |
CA2865644A1 (en) | 2013-09-19 |
HK1200271A1 (en) | 2015-08-07 |
AU2013204580B2 (en) | 2016-03-17 |
CN104302170A (en) | 2015-01-21 |
AU2013204580A8 (en) | 2016-04-07 |
AU2013204581B2 (en) | 2015-06-25 |
RU2014141536A (en) | 2016-05-10 |
CN106318951A (en) | 2017-01-11 |
WO2013138681A1 (en) | 2013-09-19 |
US9301510B2 (en) | 2016-04-05 |
AU2013204580A1 (en) | 2013-10-03 |
SG10201607727PA (en) | 2016-11-29 |
BR112014022853A2 (en) | 2017-07-18 |
MY173376A (en) | 2020-01-21 |
EP2825035A1 (en) | 2015-01-21 |
US20160229906A1 (en) | 2016-08-11 |
AU2016204066A1 (en) | 2016-07-07 |
KR20140134672A (en) | 2014-11-24 |
MX2014011047A (en) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201607727PA (en) | Mice that produce antigen-binding proteins with ph-dependent binding characteristics | |
IL271804A (en) | Mice that make binding proteins | |
HK1211603A1 (en) | Anti-pcsk9 antibodies with ph-dependent binding characteristics ph--pcsk9 | |
IL264558A (en) | Anti-il-23p19 antibodies | |
IL240838A0 (en) | Anti-lag-3 binding proteins | |
HK1207398A1 (en) | Cd3 binding polypeptides cd3 | |
IL240915A0 (en) | Dual specific binding proteins directed against tnfɑ | |
ZA201407509B (en) | Anti-fcrn antibodies | |
HK1204571A1 (en) | Protease-regulated antibodies | |
ZA201409358B (en) | Anti-siglec- 15 antibodies | |
HK1210793A1 (en) | Abd binding polypeptide | |
ZA201407079B (en) | Cdr-modified anti-siglec-15 antibody | |
HK1210186A1 (en) | Anti-h7cr antibodies h7cr | |
PL2935330T3 (en) | Anti-notch3 antibodies | |
GB201418608D0 (en) | Peridinin-chlorophyll binding proteins | |
EP2811018A4 (en) | ANTI-sAPPß ANTIBODY | |
IL235188A0 (en) | Anti-pdgf-c antibodies | |
GB201209584D0 (en) | Modified antibodies |